Today, Philips announced it has acquired PathXL, Northern Ireland-based leader in digital pathology image analysis, workflow software and educational tools to complement its IntelliSite Pathology Solution. With this move, Philips seeks to accelerate its drive to support medical institutions around the world as they move from microscopy-driven workflows to digitized pathology workflows. Financial details of the acquisition were not disclosed.
Founded in 2004 and headquartered in Belfast, Northern Ireland, PathXL offers a range of digital pathology software applications to research and education segments of pathology and bio-pharma markets. The company has approximately 30 employees, offices in the UK and USA and distributors across three continents.
Licensing Agreement with Visiopharm
Further supporting its position as a pioneer and leader in the digitization of pathology, Philips also announced today that it signed a licensing agreement with Visiopharm, Denmark-based image analysis and software provider, to offer their breast cancer panel software algorithms with its IntelliSite solution to help pathologists provide a more objective diagnosis of breast cancer.
Through strategic investments in R&D, an acquisition, partnerships and technology licenses, Philips is building a leading portfolio for the digitization of pathology, a fast-growing area in healthcare as pathology labs are looking to improve productivity and enhance quality.
Digital pathology is a fast-growing area in healthcare as pathology labs are under pressure to improve throughput and efficiency, enhance quality and equip pathologists with the best tools to fight cancer and advance precision medicine.
